The Institute of Cancer Research: Royal Cancer Hospital

Mohammed Aljarah

Caroline Joy Springer

Dan Niculescu-Duvaz

Leo Leung

Deborah Smithen

Michael Brown

Richard Marais

Haoran Tang

Natalie Miller

Alfonso Zambon

Kiri North

Ben Ayers

This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.

Lysyl oxidase inhibitors

The disclosure relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein Xand Xis each selected from CRor N; X, Xand Xis each selected from CR, CRor N, provided at least one of X, Xand Xis CRand provided only one of X, X, X, Xand Xcan be N. R, R, R, R, R, L, Land Lare as defined herein. Compounds according to Formula (I) are pharmacologically effective as lysyl oxidase (LOX) inhibitors and are believed to be useful in the treatment of, for instance, cancer.

Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors

Growing community of inventors

Manchester, United Kingdom

Mohammed Aljarah